

## Detection and location of *Helicobacter pylori* in human gastric carcinomas

Yun-Lian Tang, Run-Liang Gan, Bi-Hua Dong, Ri-Chen Jiang, Rong-Jun Tang

Yun-Lian Tang, Run-Liang Gan, Bi-Hua Dong, Ri-Chen Jiang, Rong-Jun Tang, Department of Pathology, Medical School, Nanhua University, Hengyang 421001, Hunan Province, China  
Co-correspondents: Run-Liang Gan  
Correspondence to: Professor Bi-Hua Dong, Department of Pathology, Medical School, Nanhua University, Hengyang 421001, Hunan Province, China. gan998@yahoo.com  
Telephone: +86-734-8281075  
Received: 2004-08-31 Accepted: 2004-09-02

Tang YL, Gan RL, Dong BH, Jiang RC, Tang RJ. Detection and location of *Helicobacter pylori* in human gastric carcinomas. *World J Gastroenterol* 2005; 11(9): 1387-1391  
<http://www.wjgnet.com/1007-9327/11/1387.asp>

### Abstract

**AIM:** To define the infection status of *Helicobacter pylori* in 109 patients with gastric cancers and *H pylori* localization in gastric carcinoma tissues in South China.

**METHODS:** The incidence of *H pylori* infection in gastric carcinomas was estimated by polymerase chain reaction (PCR), simultaneously; both morphological features and the localization of *H pylori* in gastric carcinomas were demonstrated by Warthin-Starry (WS) staining. The relationships between *H pylori* infection and the clinical-pathologic factors of gastric carcinomas were analyzed by software SPSS10.0.

**RESULTS:** *H pylori* was found in 42 (39.03%) and 58 (53.21%) cases of 109 patients with gastric carcinomas by PCR and WS, respectively. *H pylori* infection rate detected in gastric carcinomas by WS was higher than that by PCR ( $\chi^2 = 9.735$ ,  $P < 0.005 < 0.01$ ). WS stain showed that *H pylori* existed in the gastric antrum mucus, mucosal gland of normal tissues adjacent to gastric carcinomas and the gland, mucus pool of cancer tissues. The positive rate of *H pylori* in normal tissues adjacent to carcinomas was higher than that in cancer tissues ( $\chi^2 = 15.750$ ,  $P < 0.005 < 0.01$ ). No significant differences in age, sex, site, histological types and lymph node metastasis were found between *H pylori*-positive gastric carcinomas and *H pylori*-negative cases by both methods, but there were statistically significant differences of *H pylori* positive rate between early and advanced stage of gastric carcinomas ( $\chi^2 = 4.548$  or  $5.922$ ,  $P = 0.033$  or  $0.015 < 0.05$ ).

**CONCLUSION:** These results suggested that *H pylori* infection might play a certain role in the early stage of carcinogenesis of human gastric mucosa epithelia.

© 2005 The WJG Press and Elsevier Inc. All rights reserved.

**Key words:** Gastric carcinoma; *H pylori*; Polymerase chain reaction; Warthin-Starry staining

### INTRODUCTION

Gastric carcinoma is one of the most common human malignant cancers in the world. Although the etiopathological mechanism of human gastric cancer remains unclear until now, most researchers think that the pathogenesis of human gastric cancer is a multifactorial, multistage and multistep process<sup>[1-3]</sup>. The epidemiological and histopathological studies have shown that *Helicobacter pylori* (*H pylori*) infection is closely associated with gastric carcinogenesis<sup>[4,5]</sup> and *H pylori* infection is also one of the factors of gastric carcinogenesis studied at present<sup>[6,7]</sup>. Although there were discrepancies among epidemiological studies<sup>[8-12]</sup>, some meta-analyses indicated that the magnitude of the association of *H pylori* infection and risk of gastric cancer was ORs = 2-6<sup>[13-17]</sup>. However, the location of *H pylori* in the gastric cancer tissues, the mechanism and the stages in which *H pylori* participates in the process of gastric carcinogenesis are largely unknown. In the present study, we have detected *H pylori* DNA by polymerase chain reaction (PCR) and observed *H pylori* location in 109 cases of gastric carcinoma by Warthin-Starry (WS) stain and analyzed relationships between *H pylori* infection and the clinical-pathologic characteristics of gastric carcinomas.

### MATERIALS AND METHODS

#### Patients

All of the 109 patients had not accepted radiotherapy and chemotherapy; their histological features were diagnosed in the Pathology Department of the First Affiliated Hospital and Cancer Research Institute of Nanhua University.

Seventy-seven specimens of paraffin-embedded gastric carcinoma tissues and 32 cases of resection specimens with gastric carcinomas were collected from First Affiliated Hospital of Nanhua University in 2000-2002. The fresh tissues were cut into 300-500 mg blocks suitable for sectioning, either frozen in -70 °C deepfreezer refrigerator, or fixed in formalin and embedded in paraffin.

#### Main reagents and dispensing

The primers for *ureA* gene of *H pylori* were synthesized in Shanghai Sangon Biological Engineering Company. Phenol:chloroform:isoamyl alcohol (25:24:1), Protease K, RNase, DNA Marker, Taq DNA polymerase and dNTP were

bought from Shanghai Songon Biological Engineering Company. 1×SSC (150 mmol/L sodium chloride, 15 mmol/L citromalic acid sodium, pH 7.0), paraffin digestion buffer (150 mmol/L sodium chloride, 15 mmol/L citromalic acid sodium, 1% sodium dodecyl sulfate (SDS)), TNE (0.1 mol/L Tris, 10 mmol/L EDTA, 2.0 mol/L NaCl, 10% SDS).

### DNA extraction

DNA of *H pylori* was extracted from control cells, resection tissue and serial section of the paraffin wax embedded material as described previously<sup>[18]</sup>. PCR amplification of 411-bp fragment from the *ureA* gene of *H pylori* was carried out as described by Monstein *et al*<sup>[19]</sup>.

With 1 mL saline, 400 mg frozen fresh tissue blocks for each case of 32 human gastric carcinomas were washed thrice, sheared to microparticles in an Eppendorf tube and then suspended in 400 µL TNE buffer containing 1 mg/mL protease K, incubated at 55 °C overnight (12-24 h).

Twenty 6-µm-thick sections of gastric carcinoma tissues were cut from each case of 77 paraffin wax embedded block and placed in an Eppendorf tube and then thoroughly dewaxed in warm xylene four times and re-hydrated by passage through graded alcohols (100, 95, 75, 50% for 30 min, respectively). The supernatant was decanted with each tube vortexed again and centrifugated at 14 000 g for 3 min. The last precipitations were re-suspended and vortexed in 700 µL 1×SSC buffer. The supernatant was decanted again after another 3-min centrifugation, and the remaining ethanol was removed with a micro capillary pipette. The precipitations were dried, and then resuspended in 400 µL paraffin wax digestion buffer containing 1 mg/mL protease K, incubated for 120 h at 55 °C in a swing bed. On the fourth d, 10 µL×20 mg/mL protease K was added to each tube.

DNA of each specimen was purified by an organic extraction step. An equal volume of phenol:chloroform: isoamyl alcohol (25:24:1) was added to each sample after digestion. After 3-min centrifugation at 14 000 g, it was mixed thoroughly and centrifuged to separate the aqueous and organic layers. The upper aqueous layer containing DNA was collected and the extraction was repeated. DNA samples were precipitated with two volumes of ethanol precooled (-20 °C) and one-tenth volume of 3 mol/L sodium acetate (pH 5.2) at -20 °C for 1 h, centrifuged for 10 min of 14 000 g, dried and redissolved in 50 µL Tris-EDTA buffer containing 20 µg/µL RNase. DNA samples extracted were assayed quantitatively with ultraviolet spectrophotometer with the value of  $A_{260}/A_{280}$  from 1.7 to 2.0, finally stored at -20 °C.

### PCR amplification

Two primers for the detection of *H pylori* were designed according to DNA sequences described by Monstein *et al*<sup>[19]</sup>, and synthesized in Shanghai Sangon Biological Engineering Company. The *ureA-H pylori* primers used were the upstream: 5'GCCAATGGTAAATTAGTT; and the downstream: 5'CTCCTTAATTGTTTTTAC, to amplify a 411 bp fragment of *ureA* gene region of *H pylori* DNA. The PCR reaction mixture contained 2.5 µL 10×Taq polymerase buffer (500 mmol/L KCl, 100 mmol/L Tris-

HCl, 1.5 mmol/L MgCl<sub>2</sub> and 0.1% gelatin), 200 µmol/L dNTPs, 0.2 µmol/L primers, 1.25 u Taq polymerase and 0.25 µg DNA samples purified in a final reaction volume of 25 µL. After an initial 5-min incubation at 94 °C in the Biometra Thermal Cycler to fully denature the template DNA, the reaction mixtures were processed through 35 PCR cycles of 1-min denaturation at 94 °C, 1-min annealing at 47 °C, and 1-min extension at 72 °C, followed by 10 min at 72 °C to ensure that all the products were fully extended. Each PCR experiment included a positive control of DNA from *H pylori* NCTC 11 637 and a negative control of TE in place of DNA. Ten microliters of reaction mixtures were loaded to 1.5% agarose gel for electrophoresis. Being stained with ethidium bromide in a DNA subcell at 100 V for 30 min, the gel was then observed under ultraviolet ray. The amplified products of *ureA* gene were at the band of 411 bp. If an orange band appeared on the band of 411 bp, which was identical to the product from positive control well, the result was thought to be positive or the sample was thought to have been infected with *H pylori*.

### Warthin-Starry staining

Five-micrometers thick paraffin sections from each case of 109 gastric carcinoma tissues were mounted on slides and backed for 1 h at 60 °C. After routine dewaxing and re-hydration with deionized water, tissue sections were washed twice with 0.2 mol/L acetic acid buffer, incubated at 56 °C for 1 h in 1% silver nitrate buffer in the dark box, then dipped in developer solution and stained for 3-8 min. After dipping into distilled water at 56 °C and washed for 2 min, sections were washed once more with distilled water, then dehydrated with 100% alcohol, cleared with xylene, and mounted with neutral gum. Under microscope observation, *H pylori* was stained into buffy or black color, and the background was light yellow.

### Statistical analysis

Results of *H pylori* detection and the clinical-pathologic parameters of 109 cases of gastric carcinomas were statistically analyzed with software SPSS10.0.

## RESULTS

### PCR detection of *H pylori* in gastric carcinomas

PCR amplification products of *H pylori* DNA were presented in 42 (39.03%) cases of gastric carcinomas. Only one positive orange band was presented on the band of 411 bp from positive control and positive samples, but no amplification band was found from negative control and negative samples. PCR products were evaluated by 1.5% agarose gel electrophoresis, as shown in Figure 1. Positive bands were presented in 17 (53.12%) from frozen tissues with gastric carcinomas and in 25 (32.47%) from paraffin-section tissues with gastric carcinomas. It is quite obvious that there was a statistically significant difference between frozen tissues and paraffin sections ( $0.01 < P < 0.05$ ).

### Detection of *H pylori* by WS stain


WS stain showed 58 out of 109 cases (53.21%) of tissue sections carrying bacterial bodies of *H pylori* from 109 gastric

carcinomas, and the positive rate was higher than that detected by PCR method. Simultaneously, shape and location of *H pylori* could be clearly seen (Figure 2), *H pylori* of different sizes showed different forms such as curve, S-shape, arc or stem. In non-tumor tissues adjacent to gastric cancers, some bacteria gathered together just like shoals of fish. However, in tumor tissues, they diffused in every direction. In 25 of 58 cases with *H pylori*-positive gastric carcinomas, bacterial bodies of *H pylori* were observed in the mucus, mucosal gland cavum, epithelial cell plasmas of normal tissues adjacent to cancers. Bacterial bodies of *H pylori* in 3 of 58 cases were observed in the gland, mucous pool and plasma of cancer cells. *H pylori* was observed in both tumor and non-tumor sites in 30 of 109 cases with gastric carcinomas (Table 1). By  $\chi^2$  test ( $\chi^2 = 15.750, P < 0.005 < 0.01$ ), *H pylori* positive rate in non-tumor sites was higher than that in tumor sites.

The results of *H pylori* in 109 cases with gastric carcinomas were statistically analyzed by Pearson Chi-Square of SPSS10.0, which were  $\chi^2 = 9.735, P < 0.005 < 0.01$  (Table 2). There was significant difference in *H pylori* positive rates detected by PCR and WS methods, respectively.

**Relationships between *H pylori* infection and the clinical-pathologic characteristics of human gastric carcinomas**

On the basis of data in Table 3, the results were statistically analyzed by Pearson Chi-Square of SPSS10.0. No statistically significant differences in age, sex, site and lymph node metastasis were found between *H pylori*-positive cases and *H pylori*-negative cases of gastric carcinomas by both methods of PCR and WS.



**Figure 1** 1.5% agarose gel electrophoresis of PCR products, showing amplification of 411-bp fragment of *ureA* gene from DNA extracted.

**Table 1** Numbers of *H pylori* positive cases in different histological sites

Tumor site	No tumor site		Total
	+	-	
+	30	3	33
-	25	51	76
Total	55	54	109

**Table 2** Detection of *H pylori* by WS stain and PCR

PCR	WS stain		Total
	+	-	
+	38	4	42
-	20	47	67
Total	58	51	109

On the basis of data in Table 4, the results were statistically analyzed by Pearson Chi-Square of SPSS10.0, and no significant differences of *H pylori* detection were shown among four types of gastric carcinoma according to histological morphology by both PCR and WS stain.

The positive rates of *H pylori* DNA were 62.5 and 34.4% in 16 cases of early gastric carcinomas and 93 cases of advanced gastric carcinomas by PCR detecting *H pylori*, respectively. Whereas, the positive rates of *H pylori* were 75.0 and 49.5% in early gastric carcinomas and advanced gastric carcinomas by WS, respectively. The results showed that statistically significant differences between *H pylori*-positive gastric carcinomas and *H pylori*-negative cases were found in clinical stages of gastric carcinomas ( $\chi^2 = 4.548, 5.922, P = 0.033$  or  $P = 0.015 < 0.05$ ), and *H pylori* positive rate of early gastric carcinomas was higher than that of the advanced gastric carcinomas (Table 5).

**Table 3** Relationships between *H pylori* infection and gastric carcinomas in age, sex, site and lymph node metastasis

Factors	Total cases	<i>H pylori</i> positive		$\chi^2$	P
		PCR	WS		
Age (yr)					
≥60	29	7	11	1.999 <sup>P</sup>	0.157 <sup>P</sup>
<60	80	35	47	3.705 <sup>W</sup>	0.054 <sup>W</sup>
Sex					
Male	64	23	33	1.131 <sup>P</sup>	0.288 <sup>P</sup>
Female	45	19	25	2.500 <sup>W</sup>	0.114 <sup>W</sup>
Locus					
Gastric antrum	55	22	29	1.221 <sup>P</sup>	0.269 <sup>P</sup>
Gastric fundus and gastric corpus	54	20	29	0.079 <sup>W</sup>	0.778 <sup>W</sup>
Lymph node metastasis					
LN+	66	26	36	0.052 <sup>P</sup>	0.819 <sup>P</sup>
LN-	43	16	22	0.120 <sup>W</sup>	0.440 <sup>W</sup>

P: PCR results, W: WS results.


**Table 4** *H pylori* infection comparison with histological types of gastric carcinoma

Histological types	Total cases	PCR		WS	
		P	N	P	N
Well-differentiated adenocarcinoma	23	9	14	12	11
Poorly-differentiated adenocarcinoma	49	16	33	24	25
Signet-ring cell carcinoma	17	7	10	11	6
Mucous adenocarcinoma	20	10	10	11	9

**Table 5** Relationships between *H pylori* infection and clinical stages of gastric carcinomas

Clinical stage	Total cases	Positive		Negative		$\chi^2$	P
		PCR	WS	PCR	WS		
Early	16	10	12	6	4	4.548 <sup>P</sup>	0.033 <sup>P</sup>
Advanced	93	32	46	61	47	5.922 <sup>W</sup>	0.015 <sup>W</sup>

P: PCR results, W: WS results.



**Figure 2** *H. pylori* in different sites. A: *H. pylori* in cancer cell plasmas and cancer tissues; B: *H. pylori* in mucous pool of mucous adenocarcinoma; C: *H. pylori* in the mucus of gastric cavum; D: *H. pylori* in mucosal gland cavum, epithelial cell plasmas of normal tissues adjacent to cancer. WS stain  $\times 1\ 000$ .

## DISCUSSION

*UreA* gene ordinarily exists in the genome of *H. pylori*, so amplification of 411-bp fragment nucleotides is used to detect the presence of *H. pylori*. However, its sensibility is determined by the primers selected, the source of DNA and quantity of bacterial presented in tissues. The fragment of 411 bp of *ureA* gene was amplified by PCR to detect the presence of *H. pylori* genome in this study. The positive rate detected by PCR method was lower than that by WS stain. The possible explanation: (1) The order of magnitude of bacterial detected by PCR was over one hundred, whereas *H. pylori* existing in the section could be easily detected by WS stain when it was carefully observed under light microscope by an experienced observer; (2) When the presence of *H. pylori* genome was detected by PCR, its sensibility was closely related to the size of fragment amplified by PCR. Because the fragment amplified by PCR was longer, DNA degradation or fragmentation might take place in treatment process of tissue samples, consequently, the amplification efficiency was lower. Since major samples of gastric carcinomas in the present study were paraffin wax embedded blocks (77/109 cases), DNA degradation or fragmentation might take place in fixation and section of tissue samples and amplification efficiency was lower. The positive rate of *H. pylori* was 53.12% from fresh tissues, whereas 32.47% from paraffin wax embedded blocks. The difference might be avoided by small fragment primers to amplify DNA fragments, Fabre *et al*<sup>[20]</sup> detected the presence of *H. pylori* genome by using fresh tissues and primers to amplify 210 bp fragments, and their result showed that the positive rate by PCR was identical to that by Giemsa stain.

By WS stain technology *H. pylori* were observed under light microscope, which lied in the mucus, mucosal gland cavum, epithelial cell plasma of normal tissues adjacent to cancer and the gland, mucous pool, cancer cell plasmas of cancer tissues. But the *H. pylori* positive rate of normal tissues adjacent to cancer was higher than that of cancer tissues. In non-tumor tissues, bacteria gathered together just like shoals of fish. However, *H. pylori* diffused in every direction in tumor tissues. The reason was regarded that acidity environments in stomach were suitable for *H. pylori* breeding, but with the formation of stomach cancer, constitution structure and microenvironments of gastric mucosa were

changed correspondently, which were not suitable for *H. pylori* surviving and led to loss of *H. pylori*<sup>[21]</sup>.

In addition, *H. pylori* positive rate at early gastric cancer was higher than that at advanced gastric cancer, which suggested *H. pylori* might be partly involved in the occurrence and development process of early gastric cancer. Accumulative infection and movement of *H. pylori* might play an important role in the development of gastric cancer. *In vitro* experiments showed that *H. pylori* at low inocula stimulated cell proliferation. But at higher inocula (bacteria to cell ratio  $>100$ ), it caused a time- and concentration-dependent reduction of cell cycle, which would be arrested at G1 phase, inhibit gastric cancer cell proliferation and induce apoptosis.

*H. pylori* infection can lead to excretion of gastric acid and decrease in ascorbic acid in the gastric gland, cause gastric epithelial cell proliferation by long-term urgent and chronic damage to gastric mucosa and induce long-term tolerant inflammation response, so as to increase carcinogenesis of carcinogen. In a human model of gastric carcinogenesis, Correa thought that *H. pylori* might play a role of precursor in gastric cancer, colonic metaplasia was a high-risk -factor of gastric cancer and *H. pylori* positive colonic metaplasia along, but should also be considered as a high risk factor of gastric cancer. Cahill divided 151 patients into normal mucosa and *H. pylori* negative group, chronic active gastritis and *H. pylori* positive group, chronic atrophic gastritis group, intestinal metaplasia group and gastric carcinoma group. Gastric antral epithelial cell proliferation was assessed as the labeling index percent. The results showed that from chronic active gastritis group to gastric carcinoma one, epithelial cell proliferation increased when compared with that of normal mucosa, which was associated with *H. pylori* infection. The increase in gastric epithelial cell proliferation associated with *H. pylori* infection was not significantly different from that associated with the gastric precancerous lesions. *H. pylori* infection, however, did not seem to influence the changed gastric epithelial cell proliferation in subjects with precancerous lesions or gastric cancer, which suggested that *H. pylori* played a certain role in early gastric carcinogenesis, although it might not have so strong an influence in the later stages of the disease as that in early ones<sup>[22]</sup>. Watanabe *et al*<sup>[23]</sup> first reported that 5-wk-old Mongolian gerbils were orally inoculated with *H. pylori* and infected alone with *H. pylori* and induced gastric carcinomas, that could be located in

the pyloric region. After the 26<sup>th</sup> wk, severe active chronic gastritis, ulcers, and intestinal metaplasia could be observed in the infected animals. After the 62<sup>nd</sup> wk, adenocarcinoma had developed in the pyloric region of 37% (10/27) of the infected animals. It was found that adenocarcinoma development seemed to be closely related to intestinal metaplasia. After this, 5-wk-old Mongolian gerbils were infected with *H pylori* ATCC-43504 strain by Honda *et al.*<sup>24</sup>. It was reported that atrophic gastritis and intestinal metaplasia also appeared in the lesser curvature of the ventral mucosa 6 mo after inoculation. Eighteen months after *H pylori* inoculation, 40% (2/5) infected Mongolian gerbils showed three well-differentiated gastric cancer. Because of the use of 5-wk-old Mongolian gerbils for study, it suggested *H pylori* infection of early stage might be one of the risk-factors increasing carcinogenesis of gastric cancer. Both of the two groups showed the pathway of “*H pylori*→atrophic gastritis→intestinal metaplasia→atypical hyperplasia→intestinal-type gastric cancer”.

These results suggested that *H pylori* infection might play a certain role in the early stage of carcinogenesis of gastric mucosa epithelia.

## REFERENCES

- 1 Hiyama T, Haruma K, Kitadai Y, Masuda H, Miyamoto M, Tanaka S, Yoshihara M, Shimamoto F, Chayama K. K-ras mutation in *helicobacter pylori*-associated chronic gastritis in patients with and without gastric cancer. *Int J Cancer* 2002; **97**: 562–566
- 2 Menaker RJ, Sharaf AA, Jones NL. *Helicobacter pylori* infection and gastric cancer: host, bug, environment, or all three? *Curr Gastroenterol Rep* 2004; **6**: 429–435
- 3 Lee SG, Kim B, Yook JH, Oh ST, Lee I, Song K. TNF/LTA polymorphisms and risk for gastric cancer/duodenal ulcer in the Korean population. *Cytokine* 2004; **28**: 75–82
- 4 Fujioka T, Murakami K, Kodama M, Kagawa J, Okimoto T, Sato R. *Helicobacter pylori* and gastric carcinoma—from the view point of animal model. *Keio J Med* 2002; **51** Suppl 2: 69–73
- 5 Wang J, Chi DS, Kalin GB, Sosinski C, Miller LE, Burja I, Thomas E. *Helicobacter pylori* infection and oncogene expressions in gastric carcinoma and its precursor lesions. *Dig Dis Sci* 2002; **47**: 107–113
- 6 Leung WK, Lin SR, Ching JY, To KF, Ng EK, Chan FK, Lau JY, Sung JJ. Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on *Helicobacter pylori* eradication. *Gut* 2004; **53**: 1244–1249
- 7 Nardone G, Morgner A. *Helicobacter pylori* and gastric malignancies. *Helicobacter* 2003; **8** Suppl 1: 44–52
- 8 Hofman P, Waidner B, Hofman V, Bereswill S, Brest P, Kist M. Pathogenesis of *Helicobacter pylori* infection. *Helicobacter* 2004; **9** Suppl 1: 15–22
- 9 Inoue M, Tajima K, Matsuura A, Suzuki T, Nakamura T, Ohashi K, Nakamura S, Tominaga S. Severity of chronic atrophic gastritis and subsequent gastric cancer occurrence: a 10-year prospective cohort study in Japan. *Cancer Lett* 2000; **161**: 105–112
- 10 Hwang IR, Kodama T, Kikuchi S, Sakai K, Peterson LE, Graham DY, Yamaoka Y. Effect of interleukin 1 polymorphisms on gastric mucosal interleukin 1beta production in *Helicobacter pylori* infection. *Gastroenterology* 2002; **123**: 1793–1803
- 11 Ishizuka J, Sugiyama T, Aoyama T, Hirayama F, Tada M, Kato M, Moriuchi T, Asaka M. Molecular cloning of p53 cDNA of Mongolian gerbil and establishment of yeast p53 functional assay system. *Helicobacter* 2003; **8**: 81–89
- 12 Yamagata H, Kiyohara Y, Aoyagi K, Kato I, Iwamoto H, Nakayama K, Shimizu H, Tanizaki Y, Arima H, Shinohara N, Kondo H, Matsumoto T, Fujishima M. Impact of *Helicobacter pylori* infection on gastric cancer incidence in a general Japanese population: the Hisayama study. *Arch Intern Med* 2000; **160**: 1962–1968
- 13 Huang JQ, Sridhar S, Chen Y, Hunt RH. Meta-analysis of the relationship between *Helicobacter pylori* seropositivity and gastric cancer. *Gastroenterology* 1998; **114**: 1169–1179
- 14 Danesh J. *Helicobacter pylori* infection and gastric cancer: systematic review of the epidemiological studies. *Aliment Pharmacol Ther* 1999; **13**: 851–856
- 15 Eslick GD, Lim LL, Byles JE, Xia HH, Talley NJ. Association of *Helicobacter pylori* infection with gastric carcinoma: a meta-analysis. *Am J Gastroenterol* 1999; **94**: 2373–2379
- 16 Gastric cancer and *Helicobacter pylori*: a combined analysis of 12 case control studies nested within prospective cohorts. *Gut* 2001; **49**: 347–353
- 17 Xue FB, Xu YY, Wan Y, Pan BR, Ren J, Fan DM. Association of *H pylori* infection with gastric carcinoma: a Meta analysis. *World J Gastroenterol* 2001; **7**: 801–804
- 18 Satoh Y, Takasaka N, Hoshikawa Y, Osaki M, Ohfuji S, Ito H, Kaibara N, Kurata T, Sairenji T. Pretreatment with restriction enzyme or bovine serum albumin for effective PCR amplification of Epstein-Barr virus DNA in DNA extracted from paraffin-embedded gastric carcinoma tissue. *J Clin Microbiol* 1998; **36**: 3423–3425
- 19 Monstein HJ, Ellnebo-Svedlund K. Molecular typing of *Helicobacter pylori* by virulence-gene based multiplex PCR and RT-PCR analysis. *Helicobacter* 2002; **7**: 287–296
- 20 Fabre R, Sobhani I, Laurent-Puig P, Hedef N, Yazigi N, Vissuzaine C, Rodde I, Potet F, Mignon M, Etienne JP. Polymerase chain reaction assay for the detection of *Helicobacter pylori* in gastric biopsy specimens: comparison with culture, rapid urease test, and histopathological tests. *Gut* 1994; **35**: 905–908
- 21 McGuigan JE. *Helicobacter pylori*: the versatile pathogen. *Dig Dis* 1996; **14**: 289–303
- 22 Cahill RJ, Kilgallen C, Beattie S, Hamilton H, O’Morain C. Gastric epithelial cell kinetics in the progression from normal mucosa to gastric carcinoma. *Gut* 1996; **38**: 177–181
- 23 Watanabe T, Tada M, Nagai H, Sasaki S, Nakao M. *Helicobacter pylori* infection induces gastric cancer in mongolian gerbils. *Gastroenterology* 1998; **115**: 642–648
- 24 Honda S, Fujioka T, Tokieda M, Satoh R, Nishizono A, Nasu M. Development of *Helicobacter pylori*-induced gastric carcinoma in Mongolian gerbils. *Cancer Res* 1998; **58**: 4255–4259